1
|
Segatori VI, Cuello HA, Gulino CA, Albertó M, Venier C, Guthmann MD, Demarco IA, Alonso DF, Gabri MR. Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients. Cancer Immunol Immunother 2018; 67:1285-1296. [PMID: 29936534 PMCID: PMC11028311 DOI: 10.1007/s00262-018-2188-y] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2017] [Accepted: 06/18/2018] [Indexed: 02/07/2023]
Abstract
Antitumor strategies based on positive modulation of the immune system currently represent therapeutic options with prominent acceptance for cancer patients' treatment due to its selectivity and higher tolerance compared to chemotherapy. Racotumomab is an anti-idiotype (anti-Id) monoclonal antibody (mAb) directed to NeuGc-containing gangliosides such as NeuGcGM3, a widely reported tumor-specific neoantigen in many human cancers. Racotumomab has been approved in Latin American countries as an active immunotherapy for advanced non-small cell lung cancer (NSCLC) treatment. In this work, we evaluated the induction of Ab-dependent cell-mediated cytotoxicity (ADCC) in NSCLC patients included in a phase III clinical trial, in response to vaccination with racotumomab. The development of anti-NeuGcGM3 antibodies (Abs) in serum samples of immunized patients was first evaluated using the NeuGcGM3-expressing X63 cells, showing that racotumomab vaccination developed antigen-specific Abs that are able to recognize NeuGcGM3 expressed in tumor cell membranes. ADCC response against NeuGcGM3-expressing X63 (target) was observed in racotumomab-treated- but not in control group patients. When target cells were depleted of gangliosides by treatment with a glucosylceramide synthase inhibitor, we observed a significant reduction of the ADCC activity developed by sera from racotumomab-vaccinated patients, suggesting a target-specific response. Our data demonstrate that anti-NeuGcGM3 Abs induced by racotumomab vaccination are able to mediate an antigen-specific ADCC response against tumor cells in NSCLC patients.
Collapse
Affiliation(s)
- Valeria I Segatori
- Molecular Oncology Laboratory, National University of Quilmes, Roque Saenz Peña 352, Bernal, B1876BXD, Argentina
| | - Héctor A Cuello
- Molecular Oncology Laboratory, National University of Quilmes, Roque Saenz Peña 352, Bernal, B1876BXD, Argentina
| | - Cynthia A Gulino
- Molecular Oncology Laboratory, National University of Quilmes, Roque Saenz Peña 352, Bernal, B1876BXD, Argentina
| | - Marina Albertó
- Molecular Oncology Laboratory, National University of Quilmes, Roque Saenz Peña 352, Bernal, B1876BXD, Argentina
| | - Cecilia Venier
- Institute of Immunology, Genetics and Metabolism (INIGEM), University of Buenos Aires, Avenida Córdoba 2351, Buenos Aires, C1120AAF, Argentina
| | | | | | - Daniel F Alonso
- Molecular Oncology Laboratory, National University of Quilmes, Roque Saenz Peña 352, Bernal, B1876BXD, Argentina
| | - Mariano R Gabri
- Molecular Oncology Laboratory, National University of Quilmes, Roque Saenz Peña 352, Bernal, B1876BXD, Argentina.
| |
Collapse
|